In this Off the Cuff video, fixed income senior portfolio manager Albert Ngo discusses inflation, economic growth and possible outcomes for the market ..read more

How pharmacogenomics can prevent drug spend waste More and more Canadians are taking prescription drugs as chronic disease and mental health problems become more widespread. But prescribing can be a challenge because each person’s unique metabolic profile—informed by their unique genetics—determines which drugs will work and which will not. Empire Life has been working with Pillcheck for three years to help plan members find the right pharmaceutical treatments sooner rather than later, so they can enjoy their lives and return to work without needless delay. For employers, the savings can add ..read more

  ..read more

..read more

In a recent video, Paul Holba, CIO, reviews the key market events of 2022 and outlook for 2023. He also shares how the team’s investment strategies reflect our cautious view of the environment, but with some positive outlooks and opportunities ..read more

In my last article, I wrote about the benefits of a buy and hold strategy where an investor stayed in the market through the ups and downs of a particular investment.  ..read more

A common piece of advice for investors is that long term success doesn’t hinge on timing the market. It’s time in the market that may make the bigger difference ..read more

Key takeaways:   Tactically moving to a more defensive positioning Increased bonds, decreased equities (all portfolios except Emblem Aggressive Growth, which has no bond component) Emblem Aggressive Growth – increased US equities, decreased international equities Tactical update - December 20, 2022 We are choosing to adopt a more cautious posture and see increasingly attractive relative value in fixed income. As such, we have reduced our equity targets in the various Emblem funds and increased our fixed income targets ..read more

From the desk of CIO Paul Holba: In this latest update from the Empire Life Investments team, Paul Holba discusses how 2022 continues to be a challenging year—but it’s not all bad news. Market recap 2022 continues to be a challenging year for investors. As mentioned in my July update, the first half of the year produced some of the worst year-to-date returns in decades for many markets. At the end of the third quarter, market returns continued to incrementally trend in the wrong direction (albeit at a slower clip). However, many markets experienced a strong October rally, trimming the year’s ..read more

  ..read more